Keywords: efficacy, safety, aricept, questioned, eisai/pfizer, acetylcholinesterase, inhibitor
Efficacy And Safety Of Aricept Questioned
Article | 29 October 1997
Eisai/Pfizer's acetylcholinesterase inhibitor Aricept (donepezil) waslicensed in the UK earlier this year for the symptomatic treatment of mild-to-moderately severe ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
